IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
UP-0862716
(2004-06-07)
|
| 등록번호 |
US-7764995
(2010-08-13)
|
|
발명자
/ 주소 |
- Girouard, Steven D.
- Ross, Jeffrey
- Salo, Rodney W.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
Schwegman, Lundberg Woessner, P.A.
|
| 인용정보 |
피인용 횟수 :
16 인용 특허 :
254 |
초록
▼
A system delivers cardiac pacing therapy and chemical and/or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that re
A system delivers cardiac pacing therapy and chemical and/or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a cardiac rhythm management (CRM) device to deliver pacing pulses to enhance the effects of the one or more agents by altering myocardial wall stress and cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable CRM device.
대표청구항
▼
What is claimed is: 1. A system configured to treat a heart having a myocardial infarct region, the system comprising: one or more agents modulating myocardial tissue growth; an implantable agent delivery device containing the one or more agents and adapted to release the one or more agents to a ca
What is claimed is: 1. A system configured to treat a heart having a myocardial infarct region, the system comprising: one or more agents modulating myocardial tissue growth; an implantable agent delivery device containing the one or more agents and adapted to release the one or more agents to a cardiac region including at least portions of the myocardial infarct region; and an implantable cardiac rhythm management (CRM) device including: a pacing circuit to deliver pacing pulses to the cardiac region; a pacing controller adapted to control the delivery of the pacing pulses to enhance the modulation of myocardial tissue growth by the one or more agents, wherein the pacing controller comprises a pacing algorithm execution module programmed to execute a remodeling control therapy (RCT) pacing algorithm; a remodeling sensor adapted to sense a signal indicative of a size of the myocardial infarct region; and an agent delivery controller adapted to produce an agent delivery control signal using the sensed signal indicative of the size of the myocardial infarct region, wherein the implantable agent delivery device is adapted to release the one or more agents according to the agent delivery control signal. 2. The system of claim 1 wherein the implantable agent delivery device includes an agent reservoir containing the one or more agents and an reservoir agent level detector. 3. The system of claim 1, wherein the implantable agent delivery device is incorporated into an additional implantable device other than the implantable CRM device. 4. The system of claim 1, wherein the one or more agents alter one or more mechanical properties of tissue in the cardiac region. 5. The system of claim 1, wherein the one or more agents alter stress, work or strain in the cardiac region. 6. The system of claim 1, wherein the one or more agents promote vascularization in the cardiac region. 7. The system of claim 1, wherein the one or more agents reduce adverse remodeling of tissue in the cardiac region. 8. The system of claim 1, wherein the one or more agents modulate hypertrophic signaling in the cardiac region. 9. The system of claim 8, wherein one agent is an endothelin receptor blocker. 10. The system of claim 1, wherein the one or more agents modulate fibrosis signaling in the cardiac region. 11. The system of claim 1, wherein the one or more agents enhance localization, implantation, or proliferation of stem cells at the cardiac region. 12. The system of claim 11, wherein the one or more agents include one or more of stern cell growth factor (SCF), granulocyte colony-stimulation factor (G-CSF), granulocyte macrophage colony-stimulating growth factor (GM-CSF), stem cell homing factor (SDF-1), bone morphogenetic protein 2 (BMP-2), or Wnt protein, or a gene encoding SCF, G-CSF, GM-CSF, SDF-1, BMP-2 or a Wnt protein. 13. The system of claim 1, wherein at least one agent is a cytokine. 14. The system of claim 1, wherein at least one agent is hepatocyte growth factor (HGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), or transforming growth factor-beta (TGF-β), or a gene encoding HGF, IGF, FGF, or TGF-β. 15. The system of claim 1, wherein the pacing controller comprises a pacing algorithm execution module programmed to execute a cardiac resynchronization therapy (CRT) pacing algorithm. 16. The system of claim 1, further comprising a pacing lead connected to the implantable CRM device, the pacing lead including at least one electrode to be disposed in or near the myocardial infarct region. 17. The system of claim 16, wherein the pacing lead is an agent eluting pacing lead including the implantable agent delivery device near the at least one electrode. 18. The system of claim 1, wherein the implantable agent delivery device is configured to be incorporated into a stent to be disposed in or near the myocardial infarct region. 19. The system of claim 1, wherein the implantable agent delivery device comprises an agent eluting epicardial patch to be disposed in or near the myocardial infarct region. 20. The system of claim 1, wherein the implantable CRM device further comprises a sensor to sense a signal indicative of a need for the release of the one or more agents. 21. The system of claim 20, wherein the sensor comprises an ischemia sensor to sense a signal indicative of an ischemic condition. 22. The system of claim 20, wherein the sensor comprises an cardiac sensing circuit to sense at least one electrogram indicative of arrhythmia. 23. The system of claim 20, wherein the sensor comprises a displacement sensor to sense a signal indicative of a strain of myocardial tissue. 24. The system of claim 20, wherein the sensor comprises a sensor to sense hypertrophic signaling. 25. The system of claim 24, wherein the sensor comprises a sensor to sense the concentration of endothelin-1, brain natriuretic peptide (BNP) or p38MAPK. 26. The system of claim 20, wherein the sensor comprises a metabolic sensor to sense a signal indicative of a metabolic need of a body. 27. The system of claim 20, wherein the sensor comprises a temperature sensor to sense a signal indicative of a perfusion of thermal energy through myocardial tissue. 28. The system of claim 20, wherein the sensor comprises a metabolic sensor to sense one or more signals indicative of a cardiac metabolism level. 29. The system if claim 28, wherein the metabolic sensor includes at least one of a pH sensor, an oxygen pressure (PO2) sensor, a carbon dioxide pressure (PCO2) sensor, a glucose sensor, a creatine sensor, a C-creative protein sensor, a creatine kinase sensor, and a creatine kinase-MB sensor. 30. The system of claim 1, wherein the implantable agent delivery device comprises an electrically controlled polymer containing the one or more agents, and wherein the polymer is adapted to release the one or more agents at a rate controlled by an amplitude of the agent delivery control signal. 31. The system of claim 1, wherein the agent delivery controller comprises a command receiver to receive an external command, and wherein the agent delivery controller is adapted to produce the agent delivery control signal in response to the external command. 32. The system of claim 31, further comprising an external system communicatively coupled to the implantable CRM device, the external system including a command transmitter to transmit the external command to the implantable CRM device. 33. The system of claim 32, wherein the external system comprises a user input to receive a user command, and wherein the command transmitter is adapted to transmit the external command in response to the user command. 34. The system of claim 33, wherein the external system comprises a programmer. 35. The system of claim 33, wherein the external system comprises: an external device communicatively coupled to the implantable CRM device; a network coupled to the external device; and a remote device coupled to the network to provide for communication with the implantable CRM device from a remote location. 36. The system of claim 35, wherein the external device comprises the user input. 37. The system of claim 35, wherein the remote device comprises the user input. 38. The system of claim 1, wherein the implantable agent delivery device is communicatively coupled to the implantable CRM device via telemetry. 39. The system of claim 1, further comprising one or more pacing leads, coupled to the implantable CRM device, for delivering the pacing pulses to the cardiac region, and wherein the remodeling sensor comprises two or more piezoelectric crystals incorporated into the one or more pacing leads. 40. The system of claim 1, wherein the remodeling sensor comprises a hypertrophic sensor adapted to sense a signal indicative of a degree of myocardial hypertrophy. 41. The system of claim 1, wherein the remodeling sensor comprises a chemical sensor adapted to sense a concentration of endothelin-1, brain natriuretic peptide (BNP) or p38MAPK.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.